Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 3/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845327 | 0.90 | TACR3 (0.40) | MTHFD2TACR3SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL22845214 | 0.89 | LMNA (0.37) | MTHFD2TACR3SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL22845409 | 0.89 | TSHR (0.40) | TACR3SMN1; SMN2LMNAP2RX7HPGD | |
| SCHEMBL22845202 | 0.88 | LMNA (0.40) | TACR3SMN1; SMN2LMNAHPGDMEN1 | |
| SCHEMBL22845293 | 0.87 | HPGD (0.40) | MTHFD2TACR3SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL22845286 | 0.86 | LMNA (0.40) | MTHFD2TACR3SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL22845368 | 0.85 | PREP (0.40) | MTHFD2SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL22845369 | 0.84 | NPY2R (0.39) | MTHFD2SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL22845287 | 0.84 | LMNA (0.37) | MTHFD2TACR3SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL22845328 | 0.82 | ALDH1A1 (0.40) | MTHFD2SMN1; SMN2LMNAP2RX7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MTHFD2 2383/4885TACR3 2928/4885SMN1; SMN2 1114/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MTHFD2 2383/4885TACR3 2928/4885SMN1; SMN2 1114/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MTHFD2 2383/4885TACR3 2928/4885SMN1; SMN2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.